# ACADIA Pharmaceuticals Inc. clinical trials: 41 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 41 trials with ACADIA Pharmaceuticals Inc. as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by ACADIA Pharmaceuticals Inc.: 41 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/acadia-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 41
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 41, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 16, 2025 | NCT07284667 | ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | ACADIA Pharmaceuticals Inc. | Phase 2 | Recruiting | Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284667) |
| July 31, 2025 | NCT07095465 | Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis | ACADIA Pharmaceuticals Inc. | Phase 3 | Recruiting | Lewy Body Dementia Psychosis | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07095465) |
| June 19, 2025 | NCT07029581 | Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis | ACADIA Pharmaceuticals Inc. | Phase 2 | Recruiting | Lewy Body Dementia Psychosis | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07029581) |
| May 20, 2024 | NCT06420297 | OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome | ACADIA Pharmaceuticals Inc. | Phase 3 | Terminated | Hyperphagia in Prader-Willi Syndrome | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06420297) |
| January 8, 2024 | NCT06194799 | ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study | ACADIA Pharmaceuticals Inc. | Phase 3 | Enrolling by invitation | Alzheimer's Disease Psychosis | 752 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06194799) |
| December 15, 2023 | NCT06173531 | Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome | ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | Hyperphagia in Prader-Willi Syndrome | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06173531) |
| December 7, 2023 | NCT06159673 | ACP-204 in Adults With Alzheimer's Disease Psychosis | ACADIA Pharmaceuticals Inc. | Phase 2/3 | Recruiting | Alzheimer's Disease Psychosis | 1,074 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06159673) |
| September 27, 2022 | NCT05555615 | Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder | ACADIA Pharmaceuticals Inc. | Phase 2/3 | Terminated | Irritability Associated With Autism Spectrum Disorder | 209 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05555615) |
| August 31, 2022 | NCT05523895 | Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder | ACADIA Pharmaceuticals Inc. | Phase 2/3 | Completed | Irritability Associated With Autism Spectrum Disorder | 237 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05523895) |
| August 17, 2021 | NCT05008835 | Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee | ACADIA Pharmaceuticals Inc. | Phase 2 | Terminated | Osteoarthritis Pain | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05008835) |
| August 4, 2021 | NCT04988867 | An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome | ACADIA Pharmaceuticals Inc. | Phase 2/3 | Terminated | Rett Syndrome | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04988867) |
| April 22, 2021 | NCT04855240 | Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy | ACADIA Pharmaceuticals Inc. | Phase 2 | Completed | Acute Postoperative Pain, Bunionectomy | 239 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04855240) |
| March 2, 2021 | NCT04776746 | Open-Label Extension Study of Trofinetide for Rett Syndrome | ACADIA Pharmaceuticals Inc. | Phase 3 | Terminated | Rett Syndrome | 77 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04776746) |
| August 31, 2020 | NCT04531982 | Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia | ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | Schizophrenia | 454 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04531982) |
| March 3, 2020 | NCT04292223 | Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis | ACADIA Pharmaceuticals Inc. | Phase 4 | Completed | Parkinson Disease Psychosis | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04292223) |
| February 21, 2020 | NCT04279314 | Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome | ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | Rett Syndrome | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04279314) |
| November 29, 2019 | NCT04181723 | Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™) | ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | Rett Syndrome | 187 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04181723) |
| November 15, 2019 | NCT04164758 | Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin... | ACADIA Pharmaceuticals Inc. | Phase 2 | Terminated | Parkinson's Disease | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04164758) |
| June 27, 2019 | NCT04000009 | Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment | ACADIA Pharmaceuticals Inc. | Phase 3 | Terminated | Adjunctive Treatment of Major Depressive Disorder | 235 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04000009) |
| May 30, 2019 | NCT03968159 | Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment | ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | Adjunctive Treatment of Major Depressive Disorder | 298 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03968159) |
| August 9, 2018 | NCT03623321 | Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease | ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | Neuropsychiatric Symptoms Related to Neurodegenerative Disease | 595 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03623321) |
| July 2, 2018 | NCT03575052 | A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease | ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | Neuropsychiatric Symptoms Related to Neurodegenerative Disease | 784 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03575052) |
| March 29, 2018 | NCT03482882 | Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression | ACADIA Pharmaceuticals Inc. | Phase 2 | Completed | Treatment of Depression in Adults With Parkinson's Disease (PD) | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03482882) |
| October 30, 2017 | NCT03325556 | Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis | ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | Dementia-related Psychosis | 392 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03325556) |
| May 15, 2017 | NCT03152292 | The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study | ACADIA Pharmaceuticals Inc. | Observational | Terminated | Parkinson Disease Psychosis | 764 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03152292) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 2 | 15 |
| Phase 2/3 | 4 |
| Phase 3 | 19 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 25 |
| Terminated | 10 |
| Recruiting | 4 |
| Approved for marketing | 1 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Schizophrenia | 6 |
| Psychotic Disorders | 5 |
| Hallucinations | 5 |
| Delusions | 4 |
| Rett Syndrome | 4 |
| Parkinson Disease | 3 |
| Psychomotor Agitation | 2 |
| Pain, Postoperative | 1 |
| Depressive Disorder, Major | 1 |
| Depressive Disorder, Treatment-Resistant | 1 |
| Dementia | 1 |
| Lewy Body Disease | 1 |
| Alzheimer Disease | 1 |
| Supranuclear Palsy, Progressive | 1 |
| Corticobasal Degeneration | 1 |
| Dementia, Vascular | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Powder coating companies in the United States](https://specstream.ai/data/businesses/powder-coating-companies/united-states)
- [Dental clinics in the United States](https://specstream.ai/data/businesses/dental-clinics/united-states)
- [Sandblasting companies in the United States](https://specstream.ai/data/businesses/sandblasting-companies/united-states)
- [Equipment rental companies in the United States](https://specstream.ai/data/businesses/equipment-rental-companies/united-states)
- [Taiwanese restaurants in the United States](https://specstream.ai/data/businesses/taiwanese-restaurants/united-states)
